fda compounded tirzepatide warning 2024 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our 4-3-2026 💔❤️‍🩹👹, xoxo reta rat,

Most providers have family medicine or internal medicine backgrounds with additional obesity medicine training

Compared to other weight loss drugs, using GLP-1 agonists increases the risk of pancreatitis (inflammation of the pancreas) by 9 times, bowel obstruction (blockage of the small or large intestines) by 4.5 times, and gastroparesis (a condition that slows or stops the movement of food from the stomach to the small intestine) by 3.6 times

Pooled safety analyses examined patient-level safety data from phase 13 clinical trials in patients with T2DM

Treatment must be prescribed within a specialist weight management service and is recommended for a maximum of 2 years